At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis
- PMID: 16847588
- DOI: 10.1007/s00198-006-0107-0
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis
Abstract
Introduction: Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK.
Objective: The aim of this study was to provide a Markov cohort model platform for a multinational estimation of thresholds at which intervention becomes cost-effective and to investigate and determine the main factors behind differences in these thresholds between countries.
Results and discussion: Intervention thresholds were estimated for Australia, Germany, Japan, Sweden, Spain, the UK and USA using a societal perspective. The model was populated with as much relevant country-specific data as possible. Intervention was assumed to be given for 5 years and to decrease the risk of all osteoporotic fractures by 35%. The societal willingness to pay (WTP) for a quality-adjusted life-year (QALY) gained was set to the gross domestic product (GDP) per capita multiplied by two. In the base case analysis, the 10-year hip fracture probability at which intervention became cost-effective varied across ages and countries. For women starting therapy at an age of 70 years, the IT varied from a hip fracture probability of 5.6% in Japan to 14.7% in Spain. The main factors explaining differences in the IT between countries were the WTP for a QALY gained, fracture-related costs and intervention costs.
Conclusion: The ITs presented in this paper are appropriate for use in treatment guidelines that consider health economic aspects, and they can be used in combination with fracture risk prediction algorithms to improve the selection of patients who are suitable for osteoporotic intervention.
Similar articles
-
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.Int J Clin Pharmacol Res. 2004;24(1):1-10. Int J Clin Pharmacol Res. 2004. PMID: 15575171
-
Cost-effective osteoporosis treatment thresholds in Greece.Osteoporos Int. 2015 Jul;26(7):1949-57. doi: 10.1007/s00198-015-3055-8. Epub 2015 Mar 5. Osteoporos Int. 2015. PMID: 25740208
-
Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis.Osteoporos Int. 2025 Feb;36(2):311-322. doi: 10.1007/s00198-024-07328-6. Epub 2024 Dec 27. Osteoporos Int. 2025. PMID: 39730734
-
[Absolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosis].Clin Calcium. 2007 Jul;17(7):1029-34. Clin Calcium. 2007. PMID: 17607069 Review. Japanese.
-
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Postgrad Med. 2010. PMID: 20107292 Review.
Cited by
-
Clinical and Radiographic Outcomes of Transforaminal Lumbar Interbody Fusion in Patients with Osteoporosis.Global Spine J. 2016 Nov;6(7):660-664. doi: 10.1055/s-0036-1578804. Epub 2016 Feb 19. Global Spine J. 2016. PMID: 27781185 Free PMC article.
-
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.Osteoporos Int. 2012 Nov;23(11):2579-89. doi: 10.1007/s00198-011-1869-6. Epub 2012 Jan 6. Osteoporos Int. 2012. PMID: 22222755
-
Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):183-94. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 25973339 Free PMC article.
-
Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems.BMJ Open. 2013 Mar 11;3(3):e002508. doi: 10.1136/bmjopen-2012-002508. BMJ Open. 2013. PMID: 23482989 Free PMC article.
-
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30. Osteoporos Int. 2010. PMID: 19565175
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical